Notably, in the current study, CM-MIR143#12 showed anticancer effects on RMS by targeting the ARMS-specific chimeric gene PAX3–FOXO1, which plays an important role in promoting cell cycle progression in ARMS [40]. This evidence concerns the gene FOXO1 and alveolar rhabdomyosarcoma.